GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kolon Life Science Inc (XKRX:102940) » Definitions » Cyclically Adjusted Revenue per Share

Kolon Life Science (XKRX:102940) Cyclically Adjusted Revenue per Share : ₩14,094.84 (As of Mar. 2025)


View and export this data going back to 2009. Start your Free Trial

What is Kolon Life Science Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kolon Life Science's adjusted revenue per share for the three months ended in Mar. 2025 was ₩3,148.231. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩14,094.84 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Kolon Life Science's average Cyclically Adjusted Revenue Growth Rate was 1.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kolon Life Science was 0.60% per year. The lowest was -0.10% per year. And the median was 0.25% per year.

As of today (2025-06-01), Kolon Life Science's current stock price is ₩27950.00. Kolon Life Science's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₩14,094.84. Kolon Life Science's Cyclically Adjusted PS Ratio of today is 1.98.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kolon Life Science was 6.31. The lowest was 0.89. And the median was 2.13.


Kolon Life Science Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Kolon Life Science's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon Life Science Cyclically Adjusted Revenue per Share Chart

Kolon Life Science Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13,619.41 13,850.75 14,026.25 13,877.58 13,932.77

Kolon Life Science Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13,950.09 13,853.59 13,913.00 13,932.77 14,094.84

Competitive Comparison of Kolon Life Science's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Kolon Life Science's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kolon Life Science's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kolon Life Science's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kolon Life Science's Cyclically Adjusted PS Ratio falls into.


;
;

Kolon Life Science Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kolon Life Science's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3148.231/122.5900*122.5900
=3,148.231

Current CPI (Mar. 2025) = 122.5900.

Kolon Life Science Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 3,236.126 100.051 3,965.157
201509 2,961.510 100.111 3,626.497
201512 2,916.766 100.220 3,567.800
201603 2,997.996 100.561 3,654.744
201606 3,524.197 100.791 4,286.420
201609 2,598.750 101.461 3,139.927
201612 5,410.772 101.561 6,531.095
201703 2,244.397 102.851 2,675.148
201706 1,694.803 102.611 2,024.786
201709 1,768.452 103.491 2,094.825
201712 4,350.775 102.991 5,178.730
201803 2,413.724 104.101 2,842.422
201806 3,276.538 104.130 3,857.386
201809 2,838.608 105.651 3,293.737
201812 3,108.443 104.351 3,651.763
201903 2,788.905 104.491 3,271.977
201906 3,355.429 104.881 3,921.992
201909 3,049.351 105.200 3,553.411
201912 3,834.307 105.121 4,471.479
202003 3,251.069 105.354 3,782.939
202006 3,381.596 105.112 3,943.895
202009 3,481.650 106.198 4,019.069
202012 1,231.847 105.765 1,427.803
202103 3,487.351 107.357 3,982.168
202106 3,672.306 107.579 4,184.736
202109 3,487.373 108.759 3,930.859
202112 3,945.638 109.676 4,410.208
202203 2,528.376 111.848 2,771.204
202206 4,311.262 114.072 4,633.181
202209 3,452.670 114.715 3,689.681
202212 2,163.035 115.179 2,302.208
202303 2,746.700 116.507 2,890.099
202306 2,775.462 117.182 2,903.548
202309 2,473.378 118.964 2,548.775
202312 2,928.875 118.837 3,021.369
202403 3,377.772 120.123 3,447.137
202406 3,474.965 120.007 3,549.750
202409 2,900.564 120.861 2,942.054
202412 3,764.966 121.135 3,810.182
202503 3,148.231 122.590 3,148.231

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Kolon Life Science  (XKRX:102940) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kolon Life Science's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=27950.00/14094.84
=1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kolon Life Science was 6.31. The lowest was 0.89. And the median was 2.13.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kolon Life Science Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Kolon Life Science's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kolon Life Science Business Description

Industry
Traded in Other Exchanges
N/A
Address
110, Magokdong-ro, Gangseo-gu, One & Only Tower, Seoul, KOR
Kolon Life Science Inc develops, manufactures and sells Biopharmaceuticals, Active pharmaceutical ingredients, Antimicrobials and Water solutions. Its products include Invossa, KLS-1010, KLS-2020, Azilsartan, Besfloc etc. The company has manufacturing facilities in Chungju, Eumsung and Kimchun.

Kolon Life Science Headlines

No Headlines